← Back to Search

18F-Clofarabine PET Imaging for Cancer

Phase < 1
Recruiting
Led By Omar Mian, MD
Research Sponsored by Omar Mian
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Over 18 years of age
Patient is able to remain still for the duration of the imaging procedure (up to one hour)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 minutes after cfa pet
Awards & highlights

Study Summary

This trial will test whether a new imaging agent, 18F-Clofarabine, can be used to show pyrimidine metabolism in order to better predict whether cancer drugs will be effective.

Who is the study for?
This trial is for adults over 18 with metastatic carcinoma or adenocarcinoma, confirmed by imaging. Participants must have measurable disease, be able to stay still for an hour during imaging, and have normal organ function levels. It's not suitable for those with recent severe heart issues, significant bleeding, stroke risks, or pregnant/breastfeeding women.Check my eligibility
What is being tested?
The study tests if a new PET/CT imaging agent called 18F-Clofarabine (CFA) can effectively image cancer metabolism related to pyrimidine metabolism—a factor in how well certain cancer drugs work.See study design
What are the potential side effects?
Specific side effects of the PET imaging agent are not detailed here but generally include potential allergic reactions to the tracer substance and discomfort from remaining still during the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 years old.
Select...
I can stay still for up to an hour for a scan.
Select...
My cancer is confirmed as carcinoma or adenocarcinoma.
Select...
My cancer has spread and this was confirmed by a CT scan.
Select...
I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 minutes after cfa pet
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 minutes after cfa pet for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate CFA as a PET imaging agent
Secondary outcome measures
Adverse Events
Correlate CFA uptake with OS
Correlate CFA uptake with PFS
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-ClofarabineExperimental Treatment1 Intervention
18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy

Find a Location

Who is running the clinical trial?

Omar MianLead Sponsor
1 Previous Clinical Trials
20 Total Patients Enrolled
Omar Mian, MDPrincipal InvestigatorCleveland Clinic, Case Comprehensive Cancer Center

Media Library

18F-Clofarabine Clinical Trial Eligibility Overview. Trial Name: NCT05065736 — Phase < 1
Cancer Research Study Groups: 18F-Clofarabine
Cancer Clinical Trial 2023: 18F-Clofarabine Highlights & Side Effects. Trial Name: NCT05065736 — Phase < 1
18F-Clofarabine 2023 Treatment Timeline for Medical Study. Trial Name: NCT05065736 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for enrollment in this investigation?

"According to the data hosted on clinicaltrials.gov, this medicinal trial is currently accepting participants who fit its criteria. It was initially announced on September 1st 2022 and underwent a recent update on May 11th of that year."

Answered by AI

Have scrupulous investigations been conducted on 18F-Clofarabine in the past?

"Currently, there are 23 studies assessing the efficacy of 18F-Clofarabine with 4 trials in the advanced Phase 3. Though the majority of these investigations occur at Hershey, Pennsylvania, an expansive 578 sites have been commissioned to examine this drug."

Answered by AI

To what medical issues is 18F-Clofarabine commonly administered?

"18F-Clofarabine is a potential therapy for refractory acute lymphoblastic leukemia, acute myelocytic leukemia, and relapsed all."

Answered by AI

What is the cap on participants for this research project?

"Yes, the information provided on clinicaltrials.gov reveals that this study is actively accepting participants. This trial was first posted on September 1st 2022 and last updated on May 11th 2022. The research team needs to recruit 15 individuals from a single medical site."

Answered by AI

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Omar Mian 2022. "Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05065736.
All > Adenocarcinoma
~0 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top